Okuyucu, S.Guven, O. E.Akoglu, E.Ucar, E.Dagli, S.2024-09-182024-09-1820090022-21511748-5460https://doi.org/10.1017/S002221510900423Xhttps://hdl.handle.net/20.500.12483/12748Objective: Following a report of sudden hearing loss in a patient taking phosphodiesterase type 5 inhibitor, and a Food and Drug Administration announcement concerning this class of drugs, a study was planned to investigate if ototoxicity occurs in patients using phosphodiesterase 5 inhibitor for erectile dysfunction. Methods: Eighteen patients with erectile dysfunction who had been using phosphodiesterase 5 inhibitor were included in the study. Audiometric tests were performed on all patients, between the frequencies 250 and 16 000 Hz, before and 1, 5 and 72 hours after drug ingestion. Results: Four patients showed a unilateral threshold decrease compatible with ototoxicity criteria; this change was reversible. A statistically significant difference in pre- versus post-drug hearing thresholds was observed in the right ear at 10 000 Hz (p = 0.008). There were no statistically significant hearing threshold differences at any other frequencies (p > 0.05). Conclusion: Although temporary ototoxicity was noted in four patients, we could not find any permanent, deleterious effect of phosphodiesterase type 5 inhibitor on hearing thresholds.eninfo:eu-repo/semantics/closedAccessVardenafilSensorineural DeafnessDrug ToxicityArticle123771872210.1017/S002221510900423X191342422-s2.0-68149126337Q2WOS:000267952500004Q3